Studies of Outcomes, Risks, Costs, and Benefits

Fibroblast Growth Factor 23 and Risks of Mortality and End-Stage Renal Disease in Patients With Chronic Kidney Disease

Isakova T, for the Chronic Renal Insufficiency Cohort (CRIC) Study Group (Univ of Miami Miller School of Medicine, FL; et al) JAMA 305:2432-2439, 2011^§

Abstract

Context

A high level of the phosphate-regulating hormone fibroblast growth factor 23 (FGF-23) is associated with mortality in patients with end-stage renal disease, but little is known about its relationship with adverse outcomes in the much larger population of patients with earlier stages of chronic kidney disease.

Objective

To evaluate FGF-23 as a risk factor for adverse outcomes in patients with chronic kidney disease.

Design, Setting, and Participants

A prospective study of 3879 participants with chronic kidney disease stages 2 through 4 who enrolled in the Chronic Renal Insufficiency Cohort between June 2003 and September 2008.

Only gold members can continue reading. Log In or Register to continue

Share this:

• Click to share on Twitter (Opens in new window)
• Click to share on Facebook (Opens in new window)

Related

Related posts:

of change in daily step count over five years with insulin sensitivity and adiposity: population based cohort study Intake in Early Life and Risk of Advanced Prostate Cancer Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening Administered after Recovery from Neuromuscular Block Increases Upper Airway Collapsibility by Decreasing Genioglossus Muscle Activity in Response to Negative Pharyngeal Pressure use of rocuronium in a patient with cystic fibrosis and end-stage lung disease made safe by sugammadex reversal Neuromuscular Block: Lessons Unlearned. Part I: Definitions, Incidence, and Adverse Physiologic Effects of Residual Neuromuscular Block